(Boursier.com) — In session the action Theraclion fell -0.44% to 1.135 euros in a calm volume of exchange the day after the publication of its sales for the 1st half and the report on its development strategy.
As of June 30, 2022, the end of the 1st half, Theraclion SA achieved a turnover of 347 kE, i.e. a decrease of -61% compared to the 1st half of 2021 (885 kE). Theraclion had sold 4 Echopulse in 2021 compared to only 1 second-hand system sold in 2022. The sale of consumables increased by +45%, driven by sales of consumables for the treatment of varicose veins. The expert centers carry out a mixed activity of developing treatment protocols and commercial treatments.
Some good news
On the occasion of its financial publication, Theraclion indicates that in this first half of the year it has taken major steps in its development strategy…
On the one hand, the first patients were successfully treated with Sonovein in the United States in the center of Englewood, New Jersey, by vascular surgeons Dr Steven Elias, Dr Antonios Gasparis and Pr Nicos Labropoulos. This is a major step in the process of obtaining MA (marketing authorization) from the FDA (Food and Drug Administration). “This is a further step in focusing on key varicose vein markets, of which the United States is the largest with $5 billion in annual spending,” comments Theraclion management.
On the other hand, the first half of 2022 is marked by the acceleration of technical developments, resulting in the availability to opinion leaders of the first Sonovein HD. This version integrates the Mach30 imager from SuperSonic Imagine (Hologic) recognized as one of the best on the market. Vascular surgeons and physicians have particularly welcomed Sonovein HD and are working to optimize treatments.
Finally, the first patients were included in phase IIA of the partnership with the Cancer Center of the University of Virginia (UVA), in the United States. Breast cancer research is taking a new step. The study aims to establish the combined effect of high-intensity focused ultrasound (HIFU) and low-dose chemotherapy on the immune response to breast cancer. After a first phase on subjects at an advanced stage, this 2nd part concerns subjects at an early stage.
Yann Duchesne, Executive Chairman of Theraclion since January 2022, is rolling out a new strategy. It focuses Theraclion on improving technological performance and clinical benefits to access vein markets in the United States. In Europe, the emphasis is on the formalization of treatment protocols with KOLs (Key Opinion Leaders) in order to consolidate the clinical trials underway in the United States.
Yann Duchesne’s vision is to develop Theraclion in three therapeutic areas and in three geographical areas: varicose veins, in the United States (FDA authorization request in progress) and in Europe; the thyroid, in Europe and China; breast cancer, mainly in the United States. “Value creation consists in proving the potential of our disruptive technology through robust clinical trials in each of the three indications and in our geographies. Theraclion is advancing in strategic partnerships by indication / geography: for example Veins USA, Thryroid China, Breast USA , Veins China, Thyroid USA, …. Such partnerships will enhance our technology at its fair value. Negotiations are underway”.